• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CVAC

    CureVac N.V.

    Subscribe to $CVAC
    $CVAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: curevac.com

    Peers

    $ARCT
    $BNTX
    $MRNA

    Recent Analyst Ratings for CureVac N.V.

    DatePrice TargetRatingAnalyst
    4/25/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    6/8/2023$13.00Outperform
    SVB Securities
    1/19/2023$8.00 → $18.00Neutral → Buy
    UBS
    1/9/2023$9.00 → $21.00Hold → Buy
    Jefferies
    1/21/2022$55.00 → $20.00Neutral → Underperform
    B of A Securities
    1/18/2022$52.00Market Outperform
    JMP Securities
    10/22/2021$35.00Hold
    Deutsche Bank
    See more ratings

    CureVac N.V. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Present at the 12th International mRNA Health Conference

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.More detailed preliminary safety, tolerability and immunogenicity data from the dose escalation part of CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be shared in an oral presentation. Initial data fr

      11/4/24 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced poster presentations at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 8-10 in Houston, USA.CureVac will present, among other data, extended preliminary immunogenicity results from Part A of the dose escalation phase of its ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma. The presentation will expand on safety, tolerability and immunogenicity results of the CVGBM tr

      10/28/24 8:10:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

      Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy84% of immune responses were de novo, observed in patients without pre-existingT-cell activity against encoded cancer antigensCVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicitiesMost common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollmentTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /

      9/13/24 8:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

      Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpointsVaccine candidate based on CureVac's proprietary second-generation mRNA backboneGSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVacIn July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreementTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing

      9/12/24 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical data from CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024). Clinical data will be presented as an oral presentation on Friday, September 13, along with a poster presentation of preclinical data supporting the program's development."Cancer vaccines have tre

      9/9/24 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

      Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

      8/15/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

      First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBMPart B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac's first investigational cancer vaccine based on its proprietar

      8/15/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CureVac N.V. Financials

    Live finance-specific insights

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

      Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

      8/15/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK and CureVac to Restructure Collaboration into New Licensing Agreement

      GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

      7/3/24 2:40:00 AM ET
      $CVAC
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

      Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSKSettlement with Acuitas Therapeutics includes acknowledgment of CureVac's ownership of certain patent claims and Acuitas's licenses to selected patentsContinuation of U.S. patent litigation against Pfizer/BioNTech with trial expected to begin in Q2 2025; litigation continues under seven U.S. patents with three patents to be withdrawn due to out-licensing to Acuitas TherapeuticsProgress in German patent litigation against Pfi

      5/23/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

      Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-downStrategic collaboration signed with world-leading oncology center MD Anderson, creating unique expertise to jointly discover and develop novel cancer vaccinesAppointment of Thaminda Ramanayake as Chief Business Officer, bringing more than

      4/24/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

      CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggeredPhase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac's multiepitope cancer vaccine candidatePreclinical data with multiepitope construct in oncology shows strong T cells responses and significantly extended survival in checkpoint-inhibitor resistan

      11/14/23 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update

      Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSKInitiated Phase 1 study of cancer vaccine candidate, CVGBM, for surgically resected glioblastoma; recruitment of second dose cohort well on trackBroadened position in patent litigations by expanding the scope and asserting new intellectual property rights in Germany and the U.S.Public hearing held before the Regional Court Düsseldorf as part of German patent litigation against Pfizer/BioNTechCash and cash equivalents position of €537.9 million as of June 30, 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE

      8/17/23 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

      Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and fluCOVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65Flu: monovalent modified mRNA construct Flu-SV-mRNA elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80Reaffirming plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 30, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical c

      1/30/23 8:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

      Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studiesAll candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low dosesThe preliminary results provide strong evidence of technology for CureVac's mRNA platform; CureVac and partner GSK plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical developmentCOVID-19: monovalent modified mRNA vaccine candidate CV0501, encoding Omicron variant BA.1, successfully boosted antibody titers against BA.1 and the wild type variants and was generally well to

      1/6/23 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CureVac N.V. SEC Filings

    See more
    • SEC Form 20-F filed by CureVac N.V.

      20-F - CureVac N.V. (0001809122) (Filer)

      4/10/25 5:58:45 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      4/10/25 4:01:49 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      4/7/25 4:01:39 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      3/27/25 4:30:33 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by CureVac N.V.

      144 - CureVac N.V. (0001809122) (Subject)

      1/7/25 5:49:31 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by CureVac N.V.

      144 - CureVac N.V. (0001809122) (Subject)

      1/7/25 5:30:55 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      11/12/24 4:26:06 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      11/12/24 4:24:18 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      11/4/24 4:20:19 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by CureVac N.V.

      6-K - CureVac N.V. (0001809122) (Filer)

      11/4/24 4:15:30 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CureVac N.V. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/14/24 5:01:40 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/6/24 5:10:10 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CureVac N.V.

      SC 13G - CureVac N.V. (0001809122) (Subject)

      3/27/23 5:00:14 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/24/23 4:31:06 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/24/23 4:33:12 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/24/23 4:35:17 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/24/23 4:36:52 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/24/23 2:35:01 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      2/13/23 11:41:30 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by CureVac N.V. (Amendment)

      SC 13D/A - CureVac N.V. (0001809122) (Subject)

      11/14/22 4:02:04 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CureVac N.V. Leadership Updates

    Live Leadership Updates

    See more
    • CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

      Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Axel Sven Malkomes as Chief Financial Officer, effective November 11, 2024.Mr. Malkomes joins CureVac at a pivotal moment as the company enters a new chapter of growth and innovation, bringing over three decades of senior corporate and investment banking experience within the biotech and pharmaceutical industries."Axel's

      11/4/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

      Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (NASDAQ:CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on Nasdaq and two subsequent follow-on offerings. Under his leadership, CureVac raised over $1.6 billion in equity. Mr. Kemula will succeed Tolga Hassan, who has recently left the company to explore new opportunities closer to home. Follo

      7/11/24 7:00:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Voting Results of General Meeting

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / June 24, 2024 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company's annual general meeting.The shareholders of the Company voted in favor of all proposals. These proposals included the appointment of Thaminda Ramanayake and the reappointment of Malte Greune as members of the Management Board, both effective June 24th, 2024. Additionally, Jean Stéphenne and Mathias Hothum were reappointed as members of the supervisory board, Birgit Hofmann was appointed as a new member of t

      6/24/24 4:20:00 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

      Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areasTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024."Thaminda's extensive experience in advancing corporate strategy, business develo

      4/24/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

      Former CureVac Chief Scientific Officer to Lead Research & Development of CNS Disease Therapies Yarrow Biotechnology, Inc. ("Yarrow"), an RTW Investments, LP ("RTW") -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system ("CNS"), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer. Dr. Splawski was previously the Chief Scientific Officer and a member of the Executive Board of CureVac (NASDAQ:CVAC), where he led a team of 150 scientists developing mRNA technology and mRNA vaccines and therapeutics for infectious disease, cancer, and rare indications. Th

      7/21/23 9:00:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Appoints Alexander Zehnder as CEO From April 1, 2023

      Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi onApril 1, 2023TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 9, 2023 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023."The recent clinical validation of the power of C

      1/9/23 7:15:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.

      BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (NASDAQ:CVAC). The shareholders' agreement was originally signed on 16 June 2020. It governs, among other things, the voting behavior of the shareholders, the appointment of members to the Supervisory Board of CureVac, and certain holding periods and rights of first offer mechanisms for CureVac common shar

      1/13/22 4:45:00 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    CureVac N.V. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CureVac downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded CureVac from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      4/25/24 7:53:11 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Securities initiated coverage on CureVac with a new price target

      SVB Securities initiated coverage of CureVac with a rating of Outperform and set a new price target of $13.00

      6/8/23 7:45:44 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac upgraded by UBS with a new price target

      UBS upgraded CureVac from Neutral to Buy and set a new price target of $18.00 from $8.00 previously

      1/19/23 7:20:10 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac upgraded by Jefferies with a new price target

      Jefferies upgraded CureVac from Hold to Buy and set a new price target of $21.00 from $9.00 previously

      1/9/23 8:42:51 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac downgraded by B of A Securities with a new price target

      B of A Securities downgraded CureVac from Neutral to Underperform and set a new price target of $20.00 from $55.00 previously

      1/21/22 7:00:47 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on CureVac with a new price target

      JMP Securities initiated coverage of CureVac with a rating of Market Outperform and set a new price target of $52.00

      1/18/22 6:38:12 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on CureVac with a new price target

      Deutsche Bank initiated coverage of CureVac with a rating of Hold and set a new price target of $35.00

      10/22/21 5:47:39 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac downgraded by B of A Securities with a new price target

      B of A Securities downgraded CureVac from Buy to Neutral and set a new price target of $50.00

      6/17/21 6:21:40 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on CureVac

      Credit Suisse resumed coverage of CureVac with a rating of Underperform

      4/26/21 8:32:11 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on CureVac

      Guggenheim initiated coverage of CureVac with a rating of Neutral

      4/26/21 7:55:19 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care